Abstract
Ranpirnase (ONCONASE®, a trademark of Alfacell Corporation), a cytotoxic amphibian ribonuclease, is known to be selectively tumoricidal against cancer cells. This article briefly summarizes in vitro and in vivo tumoricidal studies of ranpirnase. It proposes mechanisms of ranpirnase based on preclinical and clinical trials. Ranpirnase significantly inhibited oxygen consumption while demonstrating improvement in several tumor physiological parameters including tumor blood flow (TBF). Ranpirnase showed chemo-sensitization with various chemotherapeutic agents in vitro and in vivo. Ranpirnase significantly reduced the tumor hypertension, the major physiological barrier of therapeutic drug delivery to solid tumors. This resulted in increased tumor penetration and selectively increased TBF. This enhanced efficacy of chemotherapeutic agents including cisplatin and doxorubicin. The possible ranpirnase-related signal transduction pathways are discussed in the context of the enhanced induction of apoptosis and inhibition of protein synthesis. As a selective cancer killer ranpirnase may be a promising candidate for improving the treatment of mesothelioma and lung cancer patients.
Keywords: Ranpirnase, ONCONASE®, mesothelioma, lung cancer, apoptosis, protein inhibition, tumor hypertension, tumor blood flow
Current Cancer Therapy Reviews
Title: Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Volume: 6 Issue: 1
Author(s): Intae Lee, Daehong Kim, Jihean Lee and Kuslima Shogen
Affiliation:
Keywords: Ranpirnase, ONCONASE®, mesothelioma, lung cancer, apoptosis, protein inhibition, tumor hypertension, tumor blood flow
Abstract: Ranpirnase (ONCONASE®, a trademark of Alfacell Corporation), a cytotoxic amphibian ribonuclease, is known to be selectively tumoricidal against cancer cells. This article briefly summarizes in vitro and in vivo tumoricidal studies of ranpirnase. It proposes mechanisms of ranpirnase based on preclinical and clinical trials. Ranpirnase significantly inhibited oxygen consumption while demonstrating improvement in several tumor physiological parameters including tumor blood flow (TBF). Ranpirnase showed chemo-sensitization with various chemotherapeutic agents in vitro and in vivo. Ranpirnase significantly reduced the tumor hypertension, the major physiological barrier of therapeutic drug delivery to solid tumors. This resulted in increased tumor penetration and selectively increased TBF. This enhanced efficacy of chemotherapeutic agents including cisplatin and doxorubicin. The possible ranpirnase-related signal transduction pathways are discussed in the context of the enhanced induction of apoptosis and inhibition of protein synthesis. As a selective cancer killer ranpirnase may be a promising candidate for improving the treatment of mesothelioma and lung cancer patients.
Export Options
About this article
Cite this article as:
Lee Intae, Kim Daehong, Lee Jihean and Shogen Kuslima, Physiological and Molecular Role of Ranpirnase on Cancer Treatment, Current Cancer Therapy Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339410790596425
DOI https://dx.doi.org/10.2174/157339410790596425 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Current Medicinal Chemistry Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Analysis of Glycosaminoglycans by Electrophoretic Approach
Current Pharmaceutical Analysis Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Preface: MicroRNA as Disease Biomarkers
MicroRNA Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry